Metraipolis › archive › dc_112d0c8e02c2

Positioning of Melflufen in Heavily Pretreated RRMM Patients: Real-World Evidence in a Rapidly Evolving Therapeutic Landscape — Europe PMC PMID:41813608

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41813608
DOI
10.1111/ejh.70156
License (as archived)
solo-consultazione
Archived
2026-11-04T13:10:35.471Z
SHA-256 of the archived text
9d772c5e250a37038c573b9476c5380cdec1933d2164726e1ea289a902ac1b67
Stable URL of this page
https://metraipolis.com/documento/dc_112d0c8e02c2

How to cite

Positioning of Melflufen in Heavily Pretreated RRMM Patients: Real-World Evidence in a Rapidly Evolving Therapeutic Landscape — Europe PMC PMID:41813608 — Europe PMC (en), https://europepmc.org/article/MED/41813608 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_112d0c8e02c2 (Metraipolis archive dc_112d0c8e02c2, sha256 9d772c5e250a37038c573b9476c5380cdec1933d2164726e1ea289a902ac1b67)
BibTeX
@misc{dc112d0c8e02c2,
  title = {Positioning of Melflufen in Heavily Pretreated RRMM Patients: Real-World Evidence in a Rapidly Evolving Therapeutic Landscape — Europe PMC PMID:41813608},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41813608},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_112d0c8e02c2; sha256 9d772c5e250a37038c573b9476c5380cdec1933d2164726e1ea289a902ac1b67},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41813608. Agents can read the archived copy with the MCP tool read_document.